Zuranolone

CHEMBL4105630 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
409.6 g/mol
LogP
4.5
Phase
4

Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

Khối lượng phân tử

409,6000 g/mol

LogP

4,50

TPSA

78,90 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1

InChI

InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1

Molecular Formula

C25H35N3O2

HBD / HBA

1 / 4

Liên kết có thể quay

3

Nguyên tử nặng

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

Yes, Zuranolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4105630. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86294073. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.